Advisers to the US Food and Drug Administration voted 16-1 on Thursday in support of full approval of Paxlovid, stating that the benefits outweigh any risks of the drug for treatment of mild to moderate Covid-19 in adults who are at high risk for severe disease, including hospitalization and death.

(SOURCE) https://www.cnn.com/2023/03/16/health/fda-committee-paxlovid-approval/index.html